Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility and Reimbursement of Next-Generation Sequencing-Based Testing for Myeloid Malignancies.

The Journal of molecular diagnostics : JMD - 1 Jan 2024

Soderquist Craig R, Freeman Christopher, Lin Wen-Hsuan, Leeman-Neill Rebecca J, Gu Yue, Carter Melissa C, Stutzel Kate C, Sigcha Evelyn, Alobeid Bachir, Fernandes Helen, Bhagat Govind, Mansukhani Mahesh M, Hsiao Susan J

Abstract excerpt

Next-generation sequencing is becoming increasingly important for the diagnosis, risk stratification, and management of patients with established or suspected myeloid malignancies. These tests are being incorporated into clinical practice guidelines and many genetic alterations now constitute disease classification criteria. However, the reimbursement for these tests is uncertain. This study analyzed the clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to High-Throughput Nucleotide Sequencing
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Neoplasms

Source

Identifiers

PMID: 37981089
DOI: 10.1016/j.jmoldx.2023.09.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility and Reimbursement of Next-Generation Sequencing-Based Testing for Myeloid Malignancies.PMID 37981089Read ↗

Impact of next generation sequencing results on clinical management in patients with hematological disorders.Semantic proximity Read ↗

Current practices and guidelines for clinical next-generation sequencing oncology testing.Semantic proximity Read ↗

Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.Semantic proximity Read ↗

Applications of next-generation sequencing in hematologic malignancies.Semantic proximity Read ↗

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.Semantic proximity Read ↗

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.Semantic proximity Read ↗

The role of next-generation sequencing in hematologic malignanciesSemantic proximity Read ↗

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine useSemantic proximity Read ↗

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasmsSemantic proximity Read ↗

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia DiagnosticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.